MARKET

BNGO

BNGO

Bionano Genomics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.030
-0.020
-0.98%
Pre Market: 2.050 +0.02 +0.99% 08:58 01/27 EST
OPEN
2.170
PREV CLOSE
2.050
HIGH
2.180
LOW
1.970
VOLUME
31.17K
TURNOVER
--
52 WEEK HIGH
15.69
52 WEEK LOW
1.810
MARKET CAP
587.04M
P/E (TTM)
-7.9984
1D
5D
1M
3M
1Y
5Y
Bionano says study suggests OGM-NGS combo better at evaluating myeloid tumors
Bionano Genomics (BNGO +2.7%) said a study evaluated the performance and clinical utility of combining OGM and a 523-gene next-generation sequencing (NGS) panel for evaluation of myeloid tumors and compared it
Seekingalpha · 23h ago
BRIEF-Bionano Genomics Announces Publication Of First Study To Combine OGM And NGS
reuters.com · 1d ago
Bionano Genomics Announces Publication of the First Study to Combine OGM and NGS to Evaluate Myeloid Cancers
Whole genome analysis by OGM together with analysis using a 523-gene NGS panel can perform better and cost less than analysis with karyotyping, FISH, and a 54-gene NGS panelFirst study to publish results using NxClinical software for simultaneous visualiza...
GlobeNewswire · 1d ago
BRIEF-Bionano Genomics Announces Publication Describing How Ogm Identified Structural Variations As Predisposing Factors Associated With Severe Covid-19
reuters.com · 01/20 13:15
Bionano Genomics Announces Publication by International COVID-19 Host Genome Structural Variation Consortium Describing How OGM Identified Structural Variations as Predisposing Factors Associated with Severe COVID-19
SAN DIEGO, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solutions for visualization, interpretation and reporting ...
GlobeNewswire · 01/20 13:00
Bionano Genomics Announces its Support for the AGMG Foundation for Genetic and Genomic Medicine and its Next Generation Fellowship & Residency Training Awards Program
SAN DIEGO, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, the leading software solutions for visualization, interpretation and reporting ...
GlobeNewswire · 01/20 02:36
BRIEF-Bionano Genomics Announces Record Daily Attendance For 2022 Symposium With 63% Increase Relative To Last Year
reuters.com · 01/19 13:34
Bionano Genomics Announces Record Daily Attendance for 2022 Symposium with 63% Increase Relative to Last Year
Average daily attendance of 565 in 2022 versus 346 in 2021Over 4,000 registrants with attendees represented from 82 countries31 oral presentations delivered across four consecutive days37 scientific posters featuring OGM in the online exhibit hallOn-demand...
GlobeNewswire · 01/19 13:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BNGO. Analyze the recent business situations of Bionano Genomics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

75.00%Strong Buy
25.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average BNGO stock price target is 11.38 with a high estimate of 14.00 and a low estimate of 9.50.
High14.00
Average11.38
Low9.50
Current 2.030
EPS
Actual
Estimate
-0.06-0.04-0.03-0.01
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 163
Institutional Holdings: 72.61M
% Owned: 25.11%
Shares Outstanding: 289.18M
TypeInstitutionsShares
Increased
54
6.43M
New
20
1.02M
Decreased
48
8.32M
Sold Out
25
1.34M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-1.11%
Healthcare Equipment & Supplies
-1.22%
Key Executives
Non-Executive Chairman/Independent Director
David Barker
President/Chief Executive Officer/Director
R. Erik Holmlin
Chief Financial Officer
Christopher Stewart
Chief Operating Officer
Mark Oldakowski
Other
Alka Chaubey
Other
Jason Priar
Director
Vincent Wong
Independent Director
Yvonne Linney
Independent Director
Albert Luderer
Independent Director
Hannah Mamuszka
Independent Director
Christopher Twomey
Independent Director
Kristiina Vuori
No Data
About BNGO
Bionano Genomics, Inc. is focused on providing optical genome mapping, solutions for genome analysis. The Company provides tools and services based primarily on its Saphyr system to scientists and clinicians conducting genetic research and patient testing. It also provides diagnostic testing services for pediatric patients suspected of neurodevelopmental disabilities. Its Saphyr system is a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to search for diagnostics and therapeutic targets and to streamline the identification of structural changes in chromosomes. The Saphyr system is consists of an instrument, chip consumables, reagents, and a suite of data analysis tools. It also provides proprietary molecular genetic diagnostic services for individuals demonstrating clinical presentations consistent with neurodevelopmental disorders, including autism spectrum disorders and other disorders of childhood development.

Webull offers kinds of BioNano Genomics Inc stock information, including NASDAQ:BNGO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BNGO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BNGO stock methods without spending real money on the virtual paper trading platform.